MICs were determined by broth microdilution according to CLSI guidelines (Clinical and Laboratory Standards Institute, 2020 ) for the following antibiotics (potency and origin): amikacin (Amukin 500 mg/2 ml for injection, S.A. Bristol-Myers Squibb, Belgium), azithromycin (100%, SMB, Brussels, Belgium), ceftazidime (2 g for IV injection, 72.5%, PAN Pharma, Luitré, France), chloramphenicol (98%, Sigma-Aldrich), ciprofloxacin (98%, Fluka, Sigma-Aldrich), colistin sulfate salt (79.6%, Sigma-Aldrich), doxycycline hyclate (86.6%, Sigma-Aldrich), meropenem (500 mg powder for solution for injection or infusion, 92%, Hospira UK Ltd., Hurley, United Kingdom), piperacillin (94.2%, Sigma-Aldrich, Maryland Heights, MO), temocillin (84%, Eumedica Pharmaceuticals, Manage, Belgium), ticarcillin disodium salt (85.2%, Sigma-Aldrich), and tobramycin (100%, Teva, Wilrijk, Belgium). Tazobactam sodium salt (92.4%, Cubist Pharmaceuticals, Lexington, MA) and avibactam (99.6%, AstraZeneca Pharmaceuticals, Waltham, MA) were used as inhibitors for β-lactamases. Berberine (chloride hydrate, 82.1%; Sigma-Aldrich), known to attenuate the MexXY-OprM/OprA-mediated aminoglycoside resistance in P. aeruginosa (Morita et al., 2016 (link)), was used to reduce AxyXY-OprZ activity.
Free full text: Click here